Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by forhandlarenon Mar 27, 2024 12:18pm
77 Views
Post# 35955740

RE:Shareprice 35% below pp price

RE:Shareprice 35% below pp priceThe current private placement was a great mistake by management. They had already secured cash for another 6 to 7 months by tax returns and loan. Why not wait for some excitment over the new plans kick in? Possibly also an anti-aging deal for a region they won't launch in.

I think that potential participants tried to sell shares in order to finance their participation with warrents attached to the new shares - but - existing shareholders want material progress like Abbvie launch before they buy more shares, no matter the price. Thereby the price goes south and if they lower the price to 5 cents the same story repeats.

The easy way out to save the private placement is the replace Howard with more or less anyone. The price would immediately surge. I wouldn't mind a junior CEO. Why not a woman with interest in the beauty market?!

<< Previous
Bullboard Posts
Next >>